1-4 of 4
Michael D’Emden
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Home Monitoring of Fasting and Postprandial Triglycerides in Late Pregnancy: A Pilot Study

Helen L. Barrett, H. David McIntyre, Michael D’Emden, Marloes Dekker Nitert, Leonie K. Callaway
Journal: Diabetes Care
Diabetes Care 2017;40(1):e1–e2
https://doi.org/10.2337/dc16-2181
Published: 08 November 2016
View article titled, Home Monitoring of Fasting and Postprandial Triglycerides in Late Pregnancy: A Pilot Study
Open the PDF for Home Monitoring of Fasting and Postprandial Triglycerides in Late Pregnancy: A Pilot Study in another window
Journal Articles

Do the New Threshold Levels for the Diagnosis of Gestational Diabetes Mellitus Correctly Identify Women at Risk?

Michael d’Emden
Journal: Diabetes Care
Diabetes Care 2014;37(2):e30
https://doi.org/10.2337/dc13-2234
Published: 11 January 2014
View article titled, Do the New Threshold Levels for the Diagnosis of Gestational Diabetes Mellitus Correctly Identify Women at Risk?
Open the PDF for Do the New Threshold Levels for the Diagnosis of Gestational Diabetes Mellitus Correctly Identify Women at Risk? in another window
Journal Articles

Effects of Fenofibrate Treatment on Cardiovascular Disease Risk in 9,795 Individuals With Type 2 Diabetes and Various Components of the Metabolic Syndrome: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study

Russell Scott, MB CHB, PHD, FRACP, Richard O'Brien, MB, PHD, FRACP, Greg Fulcher, MB, MD, FRACP, Chris Pardy, Michael d'Emden, MB BS, PHD, FRACP, Dana Tse, PHD, Marja-Riitta Taskinen, MD, Christian Ehnholm, MD, PHD, Anthony Keech, MB BS, FRACP, MSC(EPID), on behalf of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study Investigators
Journal: Diabetes Care
Diabetes Care 2009;32(3):493–498
https://doi.org/10.2337/dc08-1543
Published: 01 March 2009
View article titled, Effects of Fenofibrate Treatment on Cardiovascular Disease Risk in 9,795 Individuals With Type 2 Diabetes and Various Components of the Metabolic Syndrome: <subtitle>The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study</subtitle>
Open the PDF for Effects of Fenofibrate Treatment on Cardiovascular Disease Risk in 9,795 Individuals With Type 2 Diabetes and Various Components of the Metabolic Syndrome: <subtitle>The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study</subtitle> in another window
Includes: Supplementary data
Journal Articles

Efficacy and Safety of Atorvastatin in the Prevention of Cardiovascular End Points in Subjects With Type 2 Diabetes: The Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus (ASPEN)

Robert H. Knopp, MD, Michael d’Emden, MD, Johan G. Smilde, MD, PHD, Stuart J. Pocock, PHD, on behalf of the ASPEN Study Group
Journal: Diabetes Care
Diabetes Care 2006;29(7):1478–1485
https://doi.org/10.2337/dc05-2415
Published: 01 July 2006
View article titled, Efficacy and Safety of Atorvastatin in the Prevention of Cardiovascular End Points in Subjects With Type 2 Diabetes: <subtitle>The Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus (ASPEN)</subtitle>
Open the PDF for Efficacy and Safety of Atorvastatin in the Prevention of Cardiovascular End Points in Subjects With Type 2 Diabetes: <subtitle>The Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus (ASPEN)</subtitle> in another window